MedTrace Logo

Ladarixin With Sotorasib in Advanced NSCLC - Phase II

NCT05815186 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2024-03-29

No results posted yet for this study

Summary

Study record has been combined with NCT05815173. See NCT05815173 for summary.

Conditions

  • Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

Interventions

DRUG

Sotorasib

Sotorasib administered at the approved dose of 960mg PO once daily over 21-day treatment cycles

DRUG

Ladarixin

Ladarixin administered twice-daily at the recommended phase II dose (RP2D) (determined in the phase I portion of this trial) over 21-day treatment cycles.

Sponsors & Collaborators

Principal Investigators

  • Salman Punekar, MD · NYU Langone Health

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-30
Primary Completion
2025-04-30
Completion
2026-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05815186 on ClinicalTrials.gov